Is compounded semaglutide safe for my kidneys?

Short answer: Compounded semaglutide carries extra risks that matter especially if your kidneys are vulnerable — mainly dosing errors that can lead to overdose, severe vomiting or diarrhea, dehydration, and acute kidney injury. It is also not FDA-quality-checked for purity, strength, and sterility. And as of 2025–2026, broad compounding of semaglutide is no longer a routine legal option in the U.S. Prefer the FDA-approved products (Ozempic/Wegovy) and ask about coverage.

What “compounded” means. A compounding pharmacy mixes a version of the drug rather than dispensing the manufacturer’s FDA-approved pen. During the 2023–2024 shortage, compounded semaglutide was widely sold, often through telehealth sites and often cheaply. That situation has changed.

Where things stand (U.S.). The FDA declared the semaglutide shortage resolved on February 21, 2025, which removed the legal basis for mass-compounding. The FDA then wound down its “enforcement discretion”: smaller 503A pharmacies could compound semaglutide only until April 22, 2025, and larger 503B outsourcing facilities only until May 22, 2025. In 2026, the FDA proposed not to include semaglutide (or tirzepatide or liraglutide) on the list of drugs outsourcing facilities may compound in bulk — moving to close that pathway for good. In short, cheap, easy compounded semaglutide is no longer a routine, legal pathway the way it was.

Why kidney patients should be especially cautious.

Dosing errors. Many compounded products come in multi-dose vials that require you to draw up your own dose. As of early 2025, the FDA had received more than 455 adverse-event reports tied to compounded semaglutide (a tally the FDA has since updated to 990 as of May 31, 2026) — many from people accidentally taking too much (the FDA has described errors of 5 to 20 times the intended dose), sometimes needing hospitalization. An overdose can cause severe vomiting and diarrhea → dehydration → acute kidney injury. Careful, slow dose increases matter more when your kidneys are vulnerable.
A specific ingredient concern. The FDA has warned that some compounders used salt forms of semaglutide (such as semaglutide sodium or acetate) that are not the same active ingredient as the FDA-approved drug (Ozempic and Wegovy contain the semaglutide base), with no lawful basis for their use and unknown safety. For someone whose kidneys clear waste less efficiently, unknown ingredients are a special worry.
No independent quality control. Compounded products aren’t tested the way branded pens are for purity, potency, and sterility.
Inconsistent strength. Safe, kidney-aware use depends on a known, steady dose you can titrate slowly. Batch-to-batch variation makes that harder.

If cost is the reason. Talk to your clinician about FDA-approved options first — manufacturer savings programs, and, in the U.S., how insurance and prior authorization might cover Ozempic or Wegovy for your situation.

Bottom line. For kidney safety, the FDA-approved products are the safer choice. Compounded semaglutide adds avoidable risks — dosing errors, unverified quality, and ingredient uncertainty — that land hardest on people with vulnerable kidneys.

Full guide: Semaglutide (Ozempic/Wegovy) and Your Kidneys. See also Tirzepatide and Your Kidneys for the compounded-tirzepatide picture.

Related questions